$IONS
IONIS PHARMACEUTICALS INC

2021 Q1 Form 10-K Financial Statement

#000087401521000056 Filed on February 24, 2021

View on sec.gov

Income Statement

Concept 2021 Q1 2020 Q4 2020 Q1
Revenue $111.6M $290.3M $133.4M
YoY Change -16.32% -41.2% -55.13%
Cost Of Revenue $2.600M $3.300M $2.548M
YoY Change 2.04% 230.0% 144.76%
Gross Profit $109.0M $287.0M $130.8M
YoY Change -16.68% -41.75% -55.83%
Gross Profit Margin 97.67% 98.87% 98.09%
Selling, General & Admin $61.20M $138.9M $74.99M
YoY Change -18.39% 66.75% 9.93%
% of Gross Profit 56.15% 48.4% 57.33%
Research & Development $139.8M $170.8M $117.0M
YoY Change 19.49% 14.86% 9.96%
% of Gross Profit 128.26% 59.51% 89.44%
Depreciation & Amortization $4.400M $4.300M $3.700M
YoY Change 18.92% 7.5% 2.78%
% of Gross Profit 4.04% 1.5% 2.83%
Operating Expenses $201.0M $309.6M $74.99M
YoY Change 168.02% 33.45% 9.93%
Operating Profit -$92.00M -$22.66M -$61.13M
YoY Change 50.51% -108.7% -150.3%
Interest Expense $2.200M -$1.000M $10.99M
YoY Change -79.98% 400.0% -5.25%
% of Operating Profit
Other Income/Expense, Net $0.00 $100.0K -$99.00K
YoY Change -100.0% -125.0% -32.65%
Pretax Income -$89.74M -$23.60M -$52.95M
YoY Change 69.47% -109.9% -143.43%
Income Tax $100.0K $317.8M -$3.257M
% Of Pretax Income
Net Earnings -$89.87M -$340.3M -$48.23M
YoY Change 86.35% -284.51% -157.11%
Net Earnings / Revenue -80.53% -117.22% -36.16%
Basic Earnings Per Share -$0.64 -$2.54 -$0.35
Diluted Earnings Per Share -$0.64 -$2.44 -$0.28
COMMON SHARES
Basic Shares Outstanding 140.9M 140.0M 139.4M
Diluted Shares Outstanding 140.8M 139.4M

Balance Sheet

Concept 2021 Q1 2020 Q4 2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.820B $1.892B $2.384B
YoY Change -23.66% -24.29% 5.78%
Cash & Equivalents $414.2M $397.7M $486.2M
Short-Term Investments $1.406B $1.495B $1.898B
Other Short-Term Assets $123.8M $140.2M $122.5M
YoY Change 1.06% 0.26% 24.11%
Inventory $22.20M $22.00M $22.90M
Prepaid Expenses
Receivables $23.40M $76.20M $28.60M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $1.989B $2.131B $2.558B
YoY Change -22.23% -21.68% 7.76%
LONG-TERM ASSETS
Property, Plant & Equipment $180.4M $194.2M $164.0M
YoY Change 10.0% 26.39% 11.87%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $49.90M $36.90M $342.2M
YoY Change -85.42% 33.54% 17.96%
Total Long-Term Assets $259.2M $259.1M $532.9M
YoY Change -51.36% -49.45% 15.35%
TOTAL ASSETS
Total Short-Term Assets $1.989B $2.131B $2.558B
Total Long-Term Assets $259.2M $259.1M $532.9M
Total Assets $2.249B $2.390B $3.091B
YoY Change -27.25% -26.08% 8.99%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $9.500M $17.20M $21.20M
YoY Change -55.19% 7.05% 59.4%
Accrued Expenses $108.0M $157.9M $78.90M
YoY Change 36.88% 136.49% 24.45%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $69.50M $298.5M $4.200M
YoY Change 1554.76% -66.4%
Total Short-Term Liabilities $295.1M $583.3M $258.0M
YoY Change 14.38% 113.66% 2.18%
LONG-TERM LIABILITIES
Long-Term Debt $870.9M $523.8M $794.6M
YoY Change 9.6% -32.0% 24.62%
Other Long-Term Liabilities $402.0M $439.3M $467.8M
YoY Change -14.07% -13.06% -16.22%
Total Long-Term Liabilities $1.273B $963.1M $1.262B
YoY Change 0.83% -24.5% 5.55%
TOTAL LIABILITIES
Total Short-Term Liabilities $295.1M $583.3M $258.0M
Total Long-Term Liabilities $1.273B $963.1M $1.262B
Total Liabilities $1.568B $1.546B $1.731B
YoY Change -9.4% -0.14% 6.3%
SHAREHOLDERS EQUITY
Retained Earnings -$1.131B
YoY Change 59.89%
Common Stock $1.896B
YoY Change -13.99%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $680.6M $743.3M $1.360B
YoY Change
Total Liabilities & Shareholders Equity $2.249B $2.390B $3.091B
YoY Change -27.25% -26.08% 8.99%

Cashflow Statement

Concept 2021 Q1 2020 Q4 2020 Q1
OPERATING ACTIVITIES
Net Income -$89.87M -$340.3M -$48.23M
YoY Change 86.35% -284.51% -157.11%
Depreciation, Depletion And Amortization $4.400M $4.300M $3.700M
YoY Change 18.92% 7.5% 2.78%
Cash From Operating Activities -$54.70M $98.00M -$7.600M
YoY Change 619.74% -64.72% -107.06%
INVESTING ACTIVITIES
Capital Expenditures -$1.800M -$5.100M -$9.100M
YoY Change -80.22% -34.62% 184.38%
Acquisitions
YoY Change
Other Investing Activities $80.60M $193.0M -$85.90M
YoY Change -193.83% 32.28% 28.4%
Cash From Investing Activities $78.90M $187.9M -$95.00M
YoY Change -183.05% 35.96% 35.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $90.50M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -7.600M -521.5M -94.50M
YoY Change -91.96% -2816.15% -258.82%
NET CHANGE
Cash From Operating Activities -54.70M 98.00M -7.600M
Cash From Investing Activities 78.90M 187.9M -95.00M
Cash From Financing Activities -7.600M -521.5M -94.50M
Net Change In Cash 16.60M -235.6M -197.1M
YoY Change -108.42% -154.14% -303.2%
FREE CASH FLOW
Cash From Operating Activities -$54.70M $98.00M -$7.600M
Capital Expenditures -$1.800M -$5.100M -$9.100M
Free Cash Flow -$52.90M $103.1M $1.500M
YoY Change -3626.67% -63.9% -98.65%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020 dei Entity Central Index Key
EntityCentralIndexKey
0000874015
CY2020 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2020 dei Amendment Flag
AmendmentFlag
false
CY2020 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
CY2020 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2019 us-gaap Inventory Write Down
InventoryWriteDown
CY2020 dei Document Type
DocumentType
10-K
CY2020 dei Document Annual Report
DocumentAnnualReport
true
CY2020 dei Document Period End Date
DocumentPeriodEndDate
2020-12-31
CY2020 dei Document Transition Report
DocumentTransitionReport
false
CY2020 dei Entity File Number
EntityFileNumber
000-19125
CY2020 dei Entity Registrant Name
EntityRegistrantName
Ionis Pharmaceuticals, Inc
CY2020 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2020 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
33-0336973
CY2020 dei Entity Address Address Line1
EntityAddressAddressLine1
2855 Gazelle Court
CY2020 dei Entity Address City Or Town
EntityAddressCityOrTown
Carlsbad
CY2020 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2020 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92010
CY2020 dei City Area Code
CityAreaCode
760
CY2020 dei Local Phone Number
LocalPhoneNumber
931-9200
CY2020 dei Security12b Title
Security12bTitle
Common Stock, $.001 Par Value
CY2020 dei Trading Symbol
TradingSymbol
IONS
CY2020 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2020 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
Yes
CY2020 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2020 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2020 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2020 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2020 dei Entity Small Business
EntitySmallBusiness
false
CY2020 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2020 dei Entity Shell Company
EntityShellCompany
false
CY2020Q2 dei Entity Public Float
EntityPublicFloat
6748320336
CY2021Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
140862211
CY2020Q4 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
293161000
CY2019Q4 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
0
CY2020Q4 ions Long Term Obligations Current
LongTermObligationsCurrent
7301000
CY2019Q4 ions Long Term Obligations Current
LongTermObligationsCurrent
2026000
CY2020 us-gaap Repayments Of Long Term Lines Of Credit
RepaymentsOfLongTermLinesOfCredit
0
CY2019 us-gaap Repayments Of Long Term Lines Of Credit
RepaymentsOfLongTermLinesOfCredit
12500000
CY2018 us-gaap Repayments Of Long Term Lines Of Credit
RepaymentsOfLongTermLinesOfCredit
0
CY2017Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
365280000
CY2018 us-gaap Net Income Loss
NetIncomeLoss
273741000
CY2018 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-280000
CY2018 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
23000
CY2018 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
447965000
CY2018 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
27900000
CY2018 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
131312000
CY2018 us-gaap Minority Interest Period Increase Decrease
MinorityInterestPeriodIncreaseDecrease
-58781000
CY2018Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1187160000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
294146000
CY2019 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
6633000
CY2019 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
93000
CY2019 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
119657000
CY2019 ions Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt Redemption
AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtRedemption
77331000
CY2019 us-gaap Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt
AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
81877000
CY2019 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
56110000
CY2019 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
-85860000
CY2019 us-gaap Stock Repurchased And Retired During Period Value
StockRepurchasedAndRetiredDuringPeriodValue
34388000
CY2019 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
146574000
CY2019 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
19242000
CY2019 us-gaap Minority Interest Period Increase Decrease
MinorityInterestPeriodIncreaseDecrease
9118000
CY2019Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1684547000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-451286000
CY2020 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
3729000
CY2020 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
617000
CY2020 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
52034000
CY2020 us-gaap Minority Interest Decrease From Redemptions
MinorityInterestDecreaseFromRedemptions
544686000
CY2020 us-gaap Stock Repurchased And Retired During Period Value
StockRepurchasedAndRetiredDuringPeriodValue
90549000
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
230117000
CY2020 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
13410000
CY2020 ions Adjustments To Additional Paid In Capital Deferred Tax Liability Adjustment
AdjustmentsToAdditionalPaidInCapitalDeferredTaxLiabilityAdjustment
7714000
CY2020 us-gaap Minority Interest Period Increase Decrease
MinorityInterestPeriodIncreaseDecrease
-35480000
CY2020Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
843347000
CY2020 us-gaap Notes Issued1
NotesIssued1
0
CY2019 us-gaap Notes Issued1
NotesIssued1
439326000
CY2018 us-gaap Notes Issued1
NotesIssued1
0
CY2020 us-gaap Notes Reduction
NotesReduction
0
CY2019 us-gaap Notes Reduction
NotesReduction
375590000
CY2018 us-gaap Notes Reduction
NotesReduction
0
CY2020 us-gaap Gain Loss On Investments
GainLossOnInvestments
16540000
CY2019 us-gaap Gain Loss On Investments
GainLossOnInvestments
192000
CY2018 us-gaap Gain Loss On Investments
GainLossOnInvestments
-210000
ions Number Of Investments In Privately Held Companies That Were Revalued
NumberOfInvestmentsInPrivatelyHeldCompaniesThatWereRevalued
3
CY2020 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
1900000
CY2019 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
2200000
CY2018 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
800000
CY2020 us-gaap Use Of Estimates
UseOfEstimates
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Use of Estimates</div> <div><br/></div> <div style="display:none;"><br/></div> <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates.</div>
CY2018 us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
-300000
CY2019 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
93000
CY2019 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0
CY2018 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
3350000
CY2020 us-gaap Payments To Acquire Other Productive Assets
PaymentsToAcquireOtherProductiveAssets
5928000
CY2019 us-gaap Payments To Acquire Other Productive Assets
PaymentsToAcquireOtherProductiveAssets
5377000
CY2018 us-gaap Payments To Acquire Other Productive Assets
PaymentsToAcquireOtherProductiveAssets
4044000
CY2020 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
CY2019 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
CY2018 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
447965000
CY2020 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
617000
CY2018 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-18000
CY2020 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
25855000
CY2019 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
9041000
CY2018 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0
CY2020 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0
CY2020Q4 ions Leases And Other Obligations
LeasesAndOtherObligations
30710000
CY2019Q4 ions Leases And Other Obligations
LeasesAndOtherObligations
17569000
CY2020Q4 us-gaap Contractual Obligation Due In Next Twelve Months
ContractualObligationDueInNextTwelveMonths
329189000
CY2020Q4 us-gaap Contractual Obligation Due In Second Year
ContractualObligationDueInSecondYear
3495000
CY2020Q4 us-gaap Contractual Obligation Due In Third Year
ContractualObligationDueInThirdYear
4180000
CY2020Q4 us-gaap Contractual Obligation Due In Fourth Year
ContractualObligationDueInFourthYear
553006000
CY2020Q4 us-gaap Contractual Obligation Due In Fifth Year
ContractualObligationDueInFifthYear
3494000
CY2020Q4 us-gaap Contractual Obligation Due After Fifth Year
ContractualObligationDueAfterFifthYear
60933000
CY2020Q4 us-gaap Contractual Obligation
ContractualObligation
954297000
CY2020 ions Revenue From Contract With Customer Number Of Performance Obligations At Inception Of Contract
RevenueFromContractWithCustomerNumberOfPerformanceObligationsAtInceptionOfContract
1
CY2018 us-gaap Inventory Write Down
InventoryWriteDown
0
CY2020Q4 us-gaap Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions1
AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1
226
CY2020Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
284148000
CY2020Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
140000
CY2020Q4 us-gaap Debt And Capital Lease Obligations
DebtAndCapitalLeaseObligations
839574000
CY2019Q4 us-gaap Debt And Capital Lease Obligations
DebtAndCapitalLeaseObligations
787526000
CY2020Q4 us-gaap Long Term Debt And Capital Lease Obligations
LongTermDebtAndCapitalLeaseObligations
539112000
CY2019Q4 us-gaap Long Term Debt And Capital Lease Obligations
LongTermDebtAndCapitalLeaseObligations
785500000
CY2020Q4 us-gaap Net Income Loss
NetIncomeLoss
-340271000
CY2019Q4 us-gaap Net Income Loss
NetIncomeLoss
184415000
CY2020Q4 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
300462000
CY2020Q4 us-gaap Interest Payable Current And Noncurrent
InterestPayableCurrentAndNoncurrent
21758000
CY2020Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
101820000
CY2020Q4 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
8455000
CY2020Q4 us-gaap Deferred Rent Credit
DeferredRentCredit
17310000
CY2020Q4 us-gaap Long Term Debt And Capital Lease Obligations
LongTermDebtAndCapitalLeaseObligations
539112000
CY2020Q4 us-gaap Valuation Allowances And Reserves Period Increase Decrease
ValuationAllowancesAndReservesPeriodIncreaseDecrease
313000000
CY2020Q4 us-gaap Valuation Allowances And Reserves Period Increase Decrease
ValuationAllowancesAndReservesPeriodIncreaseDecrease
313000000
CY2019Q4 ions Incremental Common Shares Attributable To Employee Stock Purchase Plan
IncrementalCommonSharesAttributableToEmployeeStockPurchasePlan
18000
CY2018Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
0
CY2018 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2019 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2019Q4 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
196485000
CY2019Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
153303000
CY2020 ions Number Of Significant Partners
NumberOfSignificantPartners
2
CY2019 ions Number Of Significant Partners
NumberOfSignificantPartners
1
CY2020Q4 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-340272000
CY2020Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
139956000
CY2020Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.44
CY2019Q4 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
183795000
CY2019Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
140583000
CY2019Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.31
CY2019Q4 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
183795000
CY2019Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
140583000
CY2019Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.31
CY2019Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.28

Files In Submission

Name View Source Status
0000874015-21-000056-index-headers.html Edgar Link pending
0000874015-21-000056-index.html Edgar Link pending
0000874015-21-000056.txt Edgar Link pending
0000874015-21-000056-xbrl.zip Edgar Link pending
exhibit10_18.htm Edgar Link pending
exhibit10_46.htm Edgar Link pending
exhibit10_56.htm Edgar Link pending
exhibit10_61.htm Edgar Link pending
exhibit10_79.htm Edgar Link pending
exhibit10_80.htm Edgar Link pending
exhibit10_81.htm Edgar Link pending
exhibit21_1.htm Edgar Link pending
exhibit23_1.htm Edgar Link pending
exhibit31_1.htm Edgar Link pending
exhibit31_2.htm Edgar Link pending
exhibit32_1.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
form10k.htm Edgar Link pending
form10k_htm.xml Edgar Link completed
image00018.jpg Edgar Link pending
image01.jpg Edgar Link pending
image02.jpg Edgar Link pending
image04.jpg Edgar Link pending
image05.jpg Edgar Link pending
image06.jpg Edgar Link pending
image08.jpg Edgar Link pending
image09.jpg Edgar Link pending
image10.jpg Edgar Link pending
image11.jpg Edgar Link pending
image12.jpg Edgar Link pending
image13.jpg Edgar Link pending
image15.jpg Edgar Link pending
image17.jpg Edgar Link pending
image4.jpg Edgar Link pending
image5.jpg Edgar Link pending
image7.jpg Edgar Link pending
ions-20201231.xsd Edgar Link pending
ions-20201231_cal.xml Edgar Link unprocessable
ions-20201231_def.xml Edgar Link unprocessable
ions-20201231_lab.xml Edgar Link unprocessable
ions-20201231_pre.xml Edgar Link unprocessable
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R80.htm Edgar Link pending
R81.htm Edgar Link pending
R82.htm Edgar Link pending
R83.htm Edgar Link pending
R84.htm Edgar Link pending
R85.htm Edgar Link pending
R86.htm Edgar Link pending
R87.htm Edgar Link pending
R88.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending